U.S. markets closed

Pharming Group N.V. (PHAR)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
10.70+0.50 (+4.90%)
At close: 04:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close10.20
Bid5.19 x 1100
Ask10.80 x 1000
Day's Range9.52 - 10.90
52 Week Range6.10 - 12.98
Avg. Volume3,651
Market Cap727.939M
Beta (5Y Monthly)1.15
PE Ratio (TTM)36.90
EPS (TTM)0.29
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
43% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for PHAR

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Pharming Group N.V.
    ITOS: What does Argus have to say about ITOS?ITEOS THERAPEUTICS INC has an Investment Rating of HOLD; a target price of $21.000000; an Industry Subrating of High; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.
    Fair Value
    Economic Moat
    6 days agoArgus Research
View more
  • Benzinga

    Pharming's Leniolisib Goes Under Priority FDA Review For Rare Immune System Disorder

    The FDA has accepted Pharming Group NV's (NASDAQ: PHAR) marketing application seeking approval for leniolisib for rare primary immunodeficiency activated phosphoinositide 3-kinase delta syndrome (APDS) in adults and adolescents. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) goal date of March 29, 2023, aligned with a Priority Review classification. Submitted by Pharming on July 29, 2022, the application was supported by positive data from a Phase 2/3 study of leniolisib, which me

  • CNW Group

    Pharming Announces US FDA Acceptance for Priority Review of its New Drug Application for Leniolisib

    Pharming Group N.V. ("Pharming" or "the Company") (Euronext Amsterdam: PHARM) (NASDAQ: PHAR) announces that the US Food and Drug Administration (FDA) has accepted for priority review its New Drug Application (NDA) for leniolisib, an oral, selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, to treat the rare primary immunodeficiency activated phosphoinositide 3-kinase delta syndrome (APDS) in adults and adolescents 12 years of age and older in the US. The FDA has assigned a Prescription

  • PR Newswire

    CEO of Pharming to present at H.C. Wainwright 24th Annual Global Investment Conference

    Pharming Group N.V. ("Pharming") (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that its Chief Executive Officer, Sijmen de Vries, will present at the H.C. Wainwright 24th Annual Global Investment Conference, a hybrid meeting based in New York, at the Lotte Palace Hotel, September 12-14, 2022.